Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
Lists
Only you see this
Abstract
Background: High-risk B-cell acute lymphoblastic leukemia (B-ALL) remains incurable for many patients despite treatment with autologous CAR T cells or allogeneic hematopoietic cell transplant (allo-HCT). We previously demonstrated that CAR T cells can be safely administered following allo-HCT without causing graft-versus-host disease (GVHD) in a preclinical murine model (Ghosh A, Smith M et al. Nat Med 2017). Hence, we hypothesized that adding allogeneic CD19/CD22-CAR T cells to a myeloablative allo-HCT containing donor T regulatory (Treg) cells (Orca-T) would augment graft versus leukemia without increasing acute GVHD or graft failure. We administered a CD19/CD22-CAR that was previously administered as an autologous CAR (NCT03233854) to patients with B-ALL where it demonstrated a high objective overall response but limited durable remission (Spiegel, J et. al. Nat Med 2021). Here, we report clinical outcomes of the initial dose escalation of donor-derived, allogeneic CD19/CD22-CAR T cells with Orca-T in our novel clinical trial design (NCT05507827). Methods: This is a single-center, phase 1, dose escalation and expansion trial of allogeneic CD19/CD22-CAR T cells in adults with high-risk B-ALL. Myeloablative conditioning with cyclophosphamide and total body irradiation precede infusion of investigational Orca-T, which consists of infusions of HSPCs and Tregs on Day 0 and an infusion of T conventional (Tcon) cells on Day 2. Allogeneic CD19/CD22-CAR-T cells are also infused on Day 2. Single agent pharmacologic GVHD prophylaxis with tacrolimus starts on Day 3. Three dose levels (DL) of allogeneic CD19/CD22-CAR T cells are being studied: DL1 (1x106), DL2 (2x106) and DL3 (3x106) CAR+ cells/kg. The primary objective is to evaluate safety and feasibility of administering allogeneic CD19/CD22-CAR T cells in combination with Orca-T. The primary endpoint is the incidence of engraftment without Grade III to IV acute GVHD at Day 42. Key secondary objectives include efficacy outcomes, CAR persistence, and immune reconstitution. Results: To date, eight patients have been enrolled and treated: 3 on DL1, 3 on DL2, and 2 on DL3 of the dose escalation phase. The median age is 28 (range, 21-52); six (75%) patients are Hispanic. Regarding high-risk disease features, 2 patients had Ph-like ALL, 1 had TP53-mutated ALL, 7 were MRD+ post-induction, and 1 had relapsed disease. At enrollment, 3 (37%) were in an MRD- CR, 4 (50%) were in an MRD+ CR, and 1 (13%) had active disease. Seven (88%) received an HLA matched sibling donor allograft, while 1 (13%) patient received an allograft from a matched unrelated donor. CAR T cells meeting the specified release criteria were successfully manufactured for all patients. All patients engrafted with median time to neutrophil and platelet recovery of 14 days (range, 12-20) and 15 days (range, 13-19), respectively. To date, no patients have experienced aGVHD, cGVHD, graft failure, or severe infectious complications. All patients experienced CRS (Grade 1, n= 7; Grade 2, n=1); there were no cases of ICANS. At Day +42 post-treatment assessment, all patients demonstrated an MRD- CR as measured by flow cytometry and BCR::ABL1 PCR (Ph+ ALL), while 7/8 patients were MRD-negative by NGS (clonoSEQ). With a median follow-up of 190 days (range, 78-502, including 6 patients with >6 months of follow-up), all patients have an ongoing MRD- CR. At last assessment, whole blood and CD3 chimerism exceeds 95% in all patients. All patients had good expansion of allogeneic CAR in the presence of immunosuppression with tacrolimus. Although the assessment of CAR T cell persistence is ongoing, 3/3 patients, all of whom were treated on DL1, have allogeneic CAR T cells detectable beyond one year. Six of the 8 patients treated will have at least one year of follow-up by the time of the meeting. Conclusion: Here, we report very promising initial feasibility, safety and efficacy of the combination of allogeneic CD19/CD22-CAR T cells with Orca-T in patients with high-risk B-ALL. This paradigm shifting combination of allogeneic CAR T and allo-HCT resulted in 100% MRD- CR with full donor chimerism but without GVHD or severe CAR-mediated toxicity. These data, which demonstrate antigen-specific anti-tumor benefit of allogeneic CAR T cells in combination with GVHD prophylaxis mediated by Tregs and tacrolimus, have potential implications that could benefit patients with other hematologic diseases.
BibTeX
@inproceedings{muffly2024safe,
author = {Lori Muffly and Snegha Ananth and Lindsay Danley and Caroline Wagner and Diana Kordek and Kimi F. DeNoble and Ayesha Fraser and Emily Egeler and Alfonso Molina and Zachary Ehlinger and Moksha H. Desai and Hossein Daghagh and Ramya Tunuguntla and Annie Kathleen Brown and Raquel Ibáñez and Anne Marijn Kramer and Zinaida Good and Sally Arai and Laura Johnston and Robert Lowsky and Andrew R. Rezvani and Judith A. Shizuru and Lekha Mikkilineni and Parveen Shiraz and Surbhi Sidana and Wen‐Kai Weng and Vanessa E. Kennedy and Sushma Bharadwaj and Saurabh Dahiya and Matthew J. Frank and Everett Meyer and Robert S. Negrin and Steven A. Feldman and Crystal L. Mackall and Bita Sahaf and David B. Miklos and Melody Smith},
title = {{Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL}},
booktitle = {Blood},
year = {2024},
doi = {10.1182/blood-2024-211959},
}Loading related content...